Human T cell lymphotropic virus type I and cutaneous T cell leukemia/lymphoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 30 citations in OpenAlex.

1. Pathogenesis of human parvovirus B19 in rheumatic disease.Annals of the rheumatic diseases · 2000
   Review
2. Immunological study on CD3 defective cutaneous T cell lymphoma cells from a patient with Sézary syndrome.Clinical and experimental immunology · 1998
   Article
3. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.Proceedings of the National Academy of Sciences of the United States of America · 1997
   Article
4. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression.Journal of virology · 1996
   Article
5. Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response.Journal of virology · 1996
   Article
6. Infectivity of chimeric human T-cell leukemia virus type I molecular clones assessed by naked DNA inoculation.Proceedings of the National Academy of Sciences of the United States of America · 1996
   Article
7. Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma.The American journal of pathology · 1996
   Article

Corrections and comments

• Erratum issued

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as